分组1 - Bioventus reported quarterly earnings of $0.06 per share, matching the Zacks Consensus Estimate, and an increase from $0.05 per share a year ago [1] - The company achieved revenues of $138.96 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 4.82%, and up from $120.79 million year-over-year [2] - Bioventus shares have increased approximately 160.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 19.8% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $147.53 million, and for the current fiscal year, it is $0.40 on revenues of $560.78 million [7] - The Medical - Drugs industry, to which Bioventus belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]
Bioventus (BVS) Matches Q3 Earnings Estimates